Antiphospholipid antibodies-associated diffuse alveolar hemorrhage.
Identifieur interne : 000269 ( Ncbi/Merge ); précédent : 000268; suivant : 000270Antiphospholipid antibodies-associated diffuse alveolar hemorrhage.
Auteurs : Ralph Yachoui [États-Unis] ; Rahul Sehgal [États-Unis] ; Barkha Amlani [États-Unis] ; Jerry W. Goldberg [États-Unis]Source :
- Seminars in arthritis and rheumatism [ 1532-866X ] ; 2015.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Anticorps antiphospholipides (immunologie), Azathioprine (usage thérapeutique), Biopsie, Cyclophosphamide (usage thérapeutique), Femelle, Hormones corticosurrénaliennes (usage thérapeutique), Humains, Hydroxychloroquine (usage thérapeutique), Hémorragie (), Hémorragie (anatomopathologie), Hémorragie (immunologie), Hémorragie (étiologie), Maladies pulmonaires (), Maladies pulmonaires (anatomopathologie), Maladies pulmonaires (immunologie), Maladies pulmonaires (étiologie), Mâle, Méthotrexate (usage thérapeutique), Poumon (anatomopathologie), Rituximab (usage thérapeutique), Sujet âgé, Syndrome des anticorps antiphospholipides (), Syndrome des anticorps antiphospholipides (immunologie), Échange plasmatique, Études de cohortes, Études rétrospectives.
- MESH :
- anatomopathologie : Hémorragie, Maladies pulmonaires, Poumon.
- immunologie : Anticorps antiphospholipides, Hémorragie, Maladies pulmonaires, Syndrome des anticorps antiphospholipides.
- usage thérapeutique : Azathioprine, Cyclophosphamide, Hormones corticosurrénaliennes, Hydroxychloroquine, Méthotrexate, Rituximab.
- étiologie : Hémorragie, Maladies pulmonaires.
- Adulte, Adulte d'âge moyen, Biopsie, Femelle, Humains, Hémorragie, Maladies pulmonaires, Mâle, Sujet âgé, Syndrome des anticorps antiphospholipides, Échange plasmatique, Études de cohortes, Études rétrospectives.
English descriptors
- KwdEn :
- Adrenal Cortex Hormones (therapeutic use), Adult, Aged, Antibodies, Antiphospholipid (immunology), Antiphospholipid Syndrome (complications), Antiphospholipid Syndrome (immunology), Antiphospholipid Syndrome (therapy), Azathioprine (therapeutic use), Biopsy, Cohort Studies, Cyclophosphamide (therapeutic use), Female, Hemorrhage (etiology), Hemorrhage (immunology), Hemorrhage (pathology), Hemorrhage (therapy), Humans, Hydroxychloroquine (therapeutic use), Lung (pathology), Lung Diseases (etiology), Lung Diseases (immunology), Lung Diseases (pathology), Lung Diseases (therapy), Male, Methotrexate (therapeutic use), Middle Aged, Plasma Exchange, Retrospective Studies, Rituximab (therapeutic use).
- MESH :
- chemical , immunology : Antibodies, Antiphospholipid.
- chemical , therapeutic use : Adrenal Cortex Hormones, Azathioprine, Cyclophosphamide, Hydroxychloroquine, Methotrexate, Rituximab.
- complications : Antiphospholipid Syndrome.
- etiology : Hemorrhage, Lung Diseases.
- immunology : Antiphospholipid Syndrome, Hemorrhage, Lung Diseases.
- pathology : Hemorrhage, Lung, Lung Diseases.
- therapy : Antiphospholipid Syndrome, Hemorrhage, Lung Diseases.
- Adult, Aged, Biopsy, Cohort Studies, Female, Humans, Male, Middle Aged, Plasma Exchange, Retrospective Studies.
Abstract
To describe the clinical features and outcomes of 17 patients with primary antiphospholipid syndrome (PAPS) or antiphospholipid antibodies (aPL) and diffuse alveolar hemorrhage (DAH).
DOI: 10.1016/j.semarthrit.2014.10.013
PubMed: 25481816
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000275
- to stream PubMed, to step Curation: 000275
- to stream PubMed, to step Checkpoint: 000259
Links to Exploration step
pubmed:25481816Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Antiphospholipid antibodies-associated diffuse alveolar hemorrhage.</title><author><name sortKey="Yachoui, Ralph" sort="Yachoui, Ralph" uniqKey="Yachoui R" first="Ralph" last="Yachoui">Ralph Yachoui</name><affiliation wicri:level="2"><nlm:affiliation>Department of Rheumatology, Marshfield Clinic, Marshfield, 1000 N Oak Ave, WI 54449. Electronic address: yachoui.ralph@marshfieldclinic.org.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Wisconsin</region></placeName><wicri:cityArea>Department of Rheumatology, Marshfield Clinic, Marshfield, 1000 N Oak Ave</wicri:cityArea></affiliation></author><author><name sortKey="Sehgal, Rahul" sort="Sehgal, Rahul" uniqKey="Sehgal R" first="Rahul" last="Sehgal">Rahul Sehgal</name><affiliation wicri:level="2"><nlm:affiliation>Department of Rheumatology, Marshfield Clinic, Marshfield, 1000 N Oak Ave, WI 54449.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Wisconsin</region></placeName><wicri:cityArea>Department of Rheumatology, Marshfield Clinic, Marshfield, 1000 N Oak Ave</wicri:cityArea></affiliation></author><author><name sortKey="Amlani, Barkha" sort="Amlani, Barkha" uniqKey="Amlani B" first="Barkha" last="Amlani">Barkha Amlani</name><affiliation wicri:level="2"><nlm:affiliation>Department of Internal Medicine, Marshfield Clinic, Marshfield, WI.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Wisconsin</region></placeName><wicri:cityArea>Department of Internal Medicine, Marshfield Clinic, Marshfield</wicri:cityArea></affiliation></author><author><name sortKey="Goldberg, Jerry W" sort="Goldberg, Jerry W" uniqKey="Goldberg J" first="Jerry W" last="Goldberg">Jerry W. Goldberg</name><affiliation wicri:level="2"><nlm:affiliation>Department of Rheumatology, Marshfield Clinic, Marshfield, 1000 N Oak Ave, WI 54449.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Wisconsin</region></placeName><wicri:cityArea>Department of Rheumatology, Marshfield Clinic, Marshfield, 1000 N Oak Ave</wicri:cityArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:25481816</idno><idno type="pmid">25481816</idno><idno type="doi">10.1016/j.semarthrit.2014.10.013</idno><idno type="wicri:Area/PubMed/Corpus">000275</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000275</idno><idno type="wicri:Area/PubMed/Curation">000275</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000275</idno><idno type="wicri:Area/PubMed/Checkpoint">000259</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000259</idno><idno type="wicri:Area/Ncbi/Merge">000269</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Antiphospholipid antibodies-associated diffuse alveolar hemorrhage.</title><author><name sortKey="Yachoui, Ralph" sort="Yachoui, Ralph" uniqKey="Yachoui R" first="Ralph" last="Yachoui">Ralph Yachoui</name><affiliation wicri:level="2"><nlm:affiliation>Department of Rheumatology, Marshfield Clinic, Marshfield, 1000 N Oak Ave, WI 54449. Electronic address: yachoui.ralph@marshfieldclinic.org.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Wisconsin</region></placeName><wicri:cityArea>Department of Rheumatology, Marshfield Clinic, Marshfield, 1000 N Oak Ave</wicri:cityArea></affiliation></author><author><name sortKey="Sehgal, Rahul" sort="Sehgal, Rahul" uniqKey="Sehgal R" first="Rahul" last="Sehgal">Rahul Sehgal</name><affiliation wicri:level="2"><nlm:affiliation>Department of Rheumatology, Marshfield Clinic, Marshfield, 1000 N Oak Ave, WI 54449.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Wisconsin</region></placeName><wicri:cityArea>Department of Rheumatology, Marshfield Clinic, Marshfield, 1000 N Oak Ave</wicri:cityArea></affiliation></author><author><name sortKey="Amlani, Barkha" sort="Amlani, Barkha" uniqKey="Amlani B" first="Barkha" last="Amlani">Barkha Amlani</name><affiliation wicri:level="2"><nlm:affiliation>Department of Internal Medicine, Marshfield Clinic, Marshfield, WI.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Wisconsin</region></placeName><wicri:cityArea>Department of Internal Medicine, Marshfield Clinic, Marshfield</wicri:cityArea></affiliation></author><author><name sortKey="Goldberg, Jerry W" sort="Goldberg, Jerry W" uniqKey="Goldberg J" first="Jerry W" last="Goldberg">Jerry W. Goldberg</name><affiliation wicri:level="2"><nlm:affiliation>Department of Rheumatology, Marshfield Clinic, Marshfield, 1000 N Oak Ave, WI 54449.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Wisconsin</region></placeName><wicri:cityArea>Department of Rheumatology, Marshfield Clinic, Marshfield, 1000 N Oak Ave</wicri:cityArea></affiliation></author></analytic><series><title level="j">Seminars in arthritis and rheumatism</title><idno type="eISSN">1532-866X</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adrenal Cortex Hormones (therapeutic use)</term><term>Adult</term><term>Aged</term><term>Antibodies, Antiphospholipid (immunology)</term><term>Antiphospholipid Syndrome (complications)</term><term>Antiphospholipid Syndrome (immunology)</term><term>Antiphospholipid Syndrome (therapy)</term><term>Azathioprine (therapeutic use)</term><term>Biopsy</term><term>Cohort Studies</term><term>Cyclophosphamide (therapeutic use)</term><term>Female</term><term>Hemorrhage (etiology)</term><term>Hemorrhage (immunology)</term><term>Hemorrhage (pathology)</term><term>Hemorrhage (therapy)</term><term>Humans</term><term>Hydroxychloroquine (therapeutic use)</term><term>Lung (pathology)</term><term>Lung Diseases (etiology)</term><term>Lung Diseases (immunology)</term><term>Lung Diseases (pathology)</term><term>Lung Diseases (therapy)</term><term>Male</term><term>Methotrexate (therapeutic use)</term><term>Middle Aged</term><term>Plasma Exchange</term><term>Retrospective Studies</term><term>Rituximab (therapeutic use)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Anticorps antiphospholipides (immunologie)</term><term>Azathioprine (usage thérapeutique)</term><term>Biopsie</term><term>Cyclophosphamide (usage thérapeutique)</term><term>Femelle</term><term>Hormones corticosurrénaliennes (usage thérapeutique)</term><term>Humains</term><term>Hydroxychloroquine (usage thérapeutique)</term><term>Hémorragie ()</term><term>Hémorragie (anatomopathologie)</term><term>Hémorragie (immunologie)</term><term>Hémorragie (étiologie)</term><term>Maladies pulmonaires ()</term><term>Maladies pulmonaires (anatomopathologie)</term><term>Maladies pulmonaires (immunologie)</term><term>Maladies pulmonaires (étiologie)</term><term>Mâle</term><term>Méthotrexate (usage thérapeutique)</term><term>Poumon (anatomopathologie)</term><term>Rituximab (usage thérapeutique)</term><term>Sujet âgé</term><term>Syndrome des anticorps antiphospholipides ()</term><term>Syndrome des anticorps antiphospholipides (immunologie)</term><term>Échange plasmatique</term><term>Études de cohortes</term><term>Études rétrospectives</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antibodies, Antiphospholipid</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Adrenal Cortex Hormones</term><term>Azathioprine</term><term>Cyclophosphamide</term><term>Hydroxychloroquine</term><term>Methotrexate</term><term>Rituximab</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Hémorragie</term><term>Maladies pulmonaires</term><term>Poumon</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Antiphospholipid Syndrome</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Hemorrhage</term><term>Lung Diseases</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Anticorps antiphospholipides</term><term>Hémorragie</term><term>Maladies pulmonaires</term><term>Syndrome des anticorps antiphospholipides</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Antiphospholipid Syndrome</term><term>Hemorrhage</term><term>Lung Diseases</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Hemorrhage</term><term>Lung</term><term>Lung Diseases</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Antiphospholipid Syndrome</term><term>Hemorrhage</term><term>Lung Diseases</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Azathioprine</term><term>Cyclophosphamide</term><term>Hormones corticosurrénaliennes</term><term>Hydroxychloroquine</term><term>Méthotrexate</term><term>Rituximab</term></keywords><keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Hémorragie</term><term>Maladies pulmonaires</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Biopsy</term><term>Cohort Studies</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Plasma Exchange</term><term>Retrospective Studies</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Biopsie</term><term>Femelle</term><term>Humains</term><term>Hémorragie</term><term>Maladies pulmonaires</term><term>Mâle</term><term>Sujet âgé</term><term>Syndrome des anticorps antiphospholipides</term><term>Échange plasmatique</term><term>Études de cohortes</term><term>Études rétrospectives</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">To describe the clinical features and outcomes of 17 patients with primary antiphospholipid syndrome (PAPS) or antiphospholipid antibodies (aPL) and diffuse alveolar hemorrhage (DAH).</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25481816</PMID><DateCompleted><Year>2016</Year><Month>04</Month><Day>14</Day></DateCompleted><DateRevised><Year>2015</Year><Month>06</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-866X</ISSN><JournalIssue CitedMedium="Internet"><Volume>44</Volume><Issue>6</Issue><PubDate><Year>2015</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Seminars in arthritis and rheumatism</Title><ISOAbbreviation>Semin. Arthritis Rheum.</ISOAbbreviation></Journal><ArticleTitle>Antiphospholipid antibodies-associated diffuse alveolar hemorrhage.</ArticleTitle><Pagination><MedlinePgn>652-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.semarthrit.2014.10.013</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0049-0172(14)00254-6</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To describe the clinical features and outcomes of 17 patients with primary antiphospholipid syndrome (PAPS) or antiphospholipid antibodies (aPL) and diffuse alveolar hemorrhage (DAH).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We reviewed the medical records of all patients diagnosed with PAPS-associated DAH and aPL-associated DAH between January 1, 1997, and December 31, 2013, for clinical features, laboratory and radiographic findings, management, and outcomes.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 17 patients met the criteria for DAH and had aPL and 10 patients met the criteria for PAPS. The mean age at DAH diagnosis was 57.6 years. Secondary causes of DAH were ruled out. Surgical lung biopsy was performed in 6 cases, 5 of whom had bland hemorrhage. Pulmonary capillaritis was present in only 1 case. Four patients (3 with aPLs and 1 with PAPS) achieved complete remission despite receiving no treatment. The majority of patients treated received initial corticosteroids. Additionally, cyclophosphamide (2 cases), rituximab (1 case), plasma exchange (2 cases), methotrexate (1 case), azathioprine (1 case), and hydroxychloroquine (2 cases) were used. In total, 10 patients (59%) achieved complete and sustained remission with a median length of follow-up of 48 months. Four patients (23%) died (2 with PAPS and 2 with aPLs), all from uncontrolled DAH. Three patients (18%) relapsed after achieving complete remission.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">DAH is a rare complication of PAPS that can also arise de novo in aPL-positive individuals. Lung pathology shows either bland hemorrhage or capillaritis. Recognition of this unusual but known complication is important, since early diagnosis and therapy could potentially affect outcomes.</AbstractText><CopyrightInformation>Copyright © 2015 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yachoui</LastName><ForeName>Ralph</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Marshfield Clinic, Marshfield, 1000 N Oak Ave, WI 54449. Electronic address: yachoui.ralph@marshfieldclinic.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sehgal</LastName><ForeName>Rahul</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Marshfield Clinic, Marshfield, 1000 N Oak Ave, WI 54449.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amlani</LastName><ForeName>Barkha</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Marshfield Clinic, Marshfield, WI.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goldberg</LastName><ForeName>Jerry W</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Marshfield Clinic, Marshfield, 1000 N Oak Ave, WI 54449.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>10</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Semin Arthritis Rheum</MedlineTA><NlmUniqueID>1306053</NlmUniqueID><ISSNLinking>0049-0172</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000305">Adrenal Cortex Hormones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017152">Antibodies, Antiphospholipid</NameOfSubstance></Chemical><Chemical><RegistryNumber>4F4X42SYQ6</RegistryNumber><NameOfSubstance UI="D000069283">Rituximab</NameOfSubstance></Chemical><Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber><NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance></Chemical><Chemical><RegistryNumber>8N3DW7272P</RegistryNumber><NameOfSubstance UI="D003520">Cyclophosphamide</NameOfSubstance></Chemical><Chemical><RegistryNumber>MRK240IY2L</RegistryNumber><NameOfSubstance UI="D001379">Azathioprine</NameOfSubstance></Chemical><Chemical><RegistryNumber>YL5FZ2Y5U1</RegistryNumber><NameOfSubstance UI="D008727">Methotrexate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000305" MajorTopicYN="N">Adrenal Cortex Hormones</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017152" MajorTopicYN="N">Antibodies, Antiphospholipid</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016736" MajorTopicYN="N">Antiphospholipid Syndrome</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001379" MajorTopicYN="N">Azathioprine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001706" MajorTopicYN="N">Biopsy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003520" MajorTopicYN="N">Cyclophosphamide</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006470" MajorTopicYN="N">Hemorrhage</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008168" MajorTopicYN="N">Lung</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008171" MajorTopicYN="N">Lung Diseases</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008727" MajorTopicYN="N">Methotrexate</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010951" MajorTopicYN="N">Plasma Exchange</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069283" MajorTopicYN="N">Rituximab</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antiphospholipid antibodies</Keyword><Keyword MajorTopicYN="N">Diffuse alveolar hemorrhage</Keyword><Keyword MajorTopicYN="N">Primary antiphospholipid syndrome</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>06</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2014</Year><Month>10</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>10</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>12</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>12</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>4</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25481816</ArticleId><ArticleId IdType="pii">S0049-0172(14)00254-6</ArticleId><ArticleId IdType="doi">10.1016/j.semarthrit.2014.10.013</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>États-Unis</li></country><region><li>Wisconsin</li></region></list><tree><country name="États-Unis"><region name="Wisconsin"><name sortKey="Yachoui, Ralph" sort="Yachoui, Ralph" uniqKey="Yachoui R" first="Ralph" last="Yachoui">Ralph Yachoui</name></region><name sortKey="Amlani, Barkha" sort="Amlani, Barkha" uniqKey="Amlani B" first="Barkha" last="Amlani">Barkha Amlani</name><name sortKey="Goldberg, Jerry W" sort="Goldberg, Jerry W" uniqKey="Goldberg J" first="Jerry W" last="Goldberg">Jerry W. Goldberg</name><name sortKey="Sehgal, Rahul" sort="Sehgal, Rahul" uniqKey="Sehgal R" first="Rahul" last="Sehgal">Rahul Sehgal</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000269 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 000269 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:25481816
|texte= Antiphospholipid antibodies-associated diffuse alveolar hemorrhage.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:25481816" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a ChloroquineV1
| This area was generated with Dilib version V0.6.33. |  |